You are here

palovarotene

FDA Approves Ipsen’s Palovarotene for Ultra-Rare Bone Disease

BioSpace

Thu, 08/17/23 - 10:08 am

fibrodysplasia ossificans progressiva

FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron

BioSpace

Mon, 08/14/23 - 11:29 am

Revance Therapeutics

fibrodysplasia ossificans progressiva

cervical dystonia

Huntington's disease

5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year

BioSpace

Fri, 07/28/23 - 11:46 am

fibrodysplasia ossificans progressiva

Santhera Pharmaceuticals

FDA Advisory Committee Recommends Ipsen's Palovarotene as an Effective and Safe Treatment for FOP

Globe Newswire

Wed, 06/28/23 - 10:27 pm

fibrodysplasia ossificans progressiva

FDA Warms Up to Ipsen’s Post-Hoc Analysis for Rare Disease Drug Ahead of Adcomm

BioSpace

Tue, 06/27/23 - 10:19 am

fibrodysplasia ossificans progressiva

FDA agrees to give Ipsen's rare disease drug another look as palovarotene saga rumbles on

Fierce Biotech

Sun, 03/19/23 - 01:34 pm

fibrodysplasia ossificans progressiva

Ipsen's rare disease candidate rejected after mounting setbacks, delays

Fierce Biotech

Fri, 12/30/22 - 10:48 am

Trick, or treat? FDA plans Halloween adcomm for Ipsen’s second chance at rare disease drug

Endpoints

Mon, 08/22/22 - 08:10 pm

Ipsen withdraws NDA for rare bone disease treatment less than 3 months after winning priority review

Endpoints

Sat, 08/14/21 - 01:47 pm

Ipsen scraps pivotal trial as partial clinical hold drags on

Fierce Biotech

Thu, 03/26/20 - 10:40 am

clinical trials

osteochondromas

Ipsen takes €669M hit as palovarotene's prospects wither

Fierce Biotech

Thu, 02/13/20 - 10:47 am

Ipsen’s quick fix backfires

EP Vantage

Fri, 01/24/20 - 10:48 am

With clear FDA path, Clementia raises $70.2M

BioCentury

Wed, 10/31/18 - 09:52 am

Clementia Pharmaceuticals

fibrodysplasia ossificans progressiva

Clementia jumps on NDA plans for unmet rare bone disease

BioCentury

Wed, 10/24/18 - 11:44 pm

Clementia Pharmaceuticals